Effect of intravitreal dexamethasone implant on intra‐ocular cytokines and chemokines in eyes with retinal vein occlusion

Rezar‐Dreindl, Sandra; Eibenberger, Katharina; Pollreisz, Andreas; Bühl, Wolf; Georgopoulos, Michael; Krall, Christoph; Dunavoelgyi, Roman; Weigert, Günther; Kroh, Maria-Elisabeth; Schmidt‐Erfurth, Ursula; Sacu, Stefan

doi:10.1111/aos.13152

Cited by 54 publications

(40 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,21 Interestingly, however, some published reports found MCP-1 AH level to decrease with DEX injection for retinal vein occlusion-derived macular edema. 32 By means of the current results, we have proven MCP-1 to be directly related to MV change in DME under DEX treatment. This finding is consistent with the general understanding of the steroid effect on DME and, moreover, highlights this molecule as a crucial role-playing agent in DME.…”

Section: Discussionmentioning

confidence: 50%

Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema

Figueras‐Roca

Sala‐Puigdollers

Zarranz‐Ventura

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. To determine whether baseline cytokine aqueous humor (AH) levels are associated with diabetic macular edema (DME) anatomic response to dexamethasone intravitreal implant (DEX) injection. METHODS. This was a prospective cohort study of DME cases receiving DEX treatment. Seventy patients were recruited with center-involving DME with spectral-domain (SD) optical coherence tomography (OCT) detection of central macular thickness (CMT) ‡300 lm on macular cube 518 3 128-lm scan protocol (Cirrus SD-OCT). DEX injection and anterior chamber tap to obtain an AH sample were performed at the same time. Multiplex immunoassay was carried out for interleukin (IL)-1b, IL-3, IL-6, IL-8, IL-10; monocyte chemoattractant protein (MCP)-1; interferon gamma-induced protein (IP)-10; tumor necrosis factor (TNF)-a; and vascular endothelial growth factor (VEGF). A follow-up visit and OCT exam were undertaken 6 to 8 weeks afterward. The association between AH cytokine baseline levels and change in CMT and macular volume (MV) was defined as main outcome measure. RESULTS. Multivariate linear regression analysis showed a higher decrease in MV to be associated (R s of 0.512) with four baseline items: higher MCP-1 (b ¼ À0.4; P ¼ 0.028), higher CMT (b ¼ À0.003; P ¼ 0.024), decreased visual acuity (b ¼ À0.7; P ¼ 0.040), and a diffuse retinal thickening (DRT) OCT pattern (b ¼ À1.3; P < 0.001). Logistic regression found DRT also to be associated with higher odds of a good MV response (odds ratio, 31.96; 95% confidence interval [CI] 7.11-143.72; P < 0.001). CONCLUSIONS. Even though visual acuity response and anatomic effect are not always correlated in DME, we found that baseline elevated MCP-1 AH levels and DRT pattern were biomarkers that predicted a future favorable anatomic response to DEX.

show abstract

Section: Discussionmentioning

confidence: 50%

Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema

Figueras‐Roca

Sala‐Puigdollers

Zarranz‐Ventura

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…The safety and efficacy profile after a second treatment with DEX implant was generally similar to that seen after the first treatment, and patients who had delayed treatment never matched the improvement of those treated earlier in the disease process [146, 147]. The ORVO study ( n = 17) also demonstrated that Ozurdex can reduce several propermeability proteins such as persephin, pentraxin 3, hepatocyte growth factor, endocrine gland VEGF, insulin-like growth factor binding proteins, and proinflammatory cytokines like MCP-1 and IL17-E [148, 149]. Also, the SHASTA study ( n = 289) demonstrated that the visual acuity and central retinal thickness significantly improved both after initial or retreatment.…”

Section: Treatmentmentioning

confidence: 96%

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Paulus

Shuai

et al. 2017

Journal of Ophthalmology

View full text Add to dashboard Cite

For years, branch retinal vein occlusion is still a controversial disease in many aspects. An increasing amount of data is available regarding classification, pathogenesis, risk factors, natural history, and therapy of branch retinal vein occlusion. Some of the conclusions may even change our impression of branch retinal vein occlusion. It will be beneficial for our doctors to get a deeper understanding of this disease and improve the treatment skills. The aims of this review is to collect the information above and report new ideas especially from the past a few years.

show abstract

“…; Rezar‐Dreindl et al. ). However, the results of these studies have not been conclusive due to their retrospective nature or small sample size.…”

Section: Introductionmentioning

confidence: 99%

Head‐to‐head comparison of ranibizumab PRN versus single‐dose dexamethasone for branch retinal vein occlusion (COMRADE‐B)

Hattenbach

Feltgen

Bertelmann

et al. 2017

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

Effect of intravitreal dexamethasone implant on intra‐ocular cytokines and chemokines in eyes with retinal vein occlusion

Abstract: Intravitreal dexamethasone treatment resulted in alterations in the concentrations of pro-inflammatory cytokines MCP-1 and IL17-E in patients with BRVO and MCP-1 and IL1-α in patients with CRVO. These data highlight the important role of inflammatory mediators involved in ME due to RVO.

Cited by 54 publications

References 37 publications

Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema

Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Head‐to‐head comparison of ranibizumab PRN versus single‐dose dexamethasone for branch retinal vein occlusion (COMRADE‐B)

Contact Info

Product

Resources

About